Calamos Advisors LLC Sells 244,349 Shares of Boston Scientific Corporation $BSX

Calamos Advisors LLC reduced its position in shares of Boston Scientific Corporation (NYSE:BSX) by 21.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 894,430 shares of the medical equipment provider’s stock after selling 244,349 shares during the period. Calamos Advisors LLC owned approximately 0.06% of Boston Scientific worth $87,323,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of BSX. Steph & Co. acquired a new position in shares of Boston Scientific during the 3rd quarter worth $25,000. 1248 Management LLC bought a new position in Boston Scientific in the first quarter valued at about $26,000. FWL Investment Management LLC bought a new position in Boston Scientific in the second quarter valued at about $26,000. Sound Income Strategies LLC raised its stake in Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 120 shares in the last quarter. Finally, Kilter Group LLC acquired a new position in Boston Scientific during the second quarter worth about $30,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Shares of Boston Scientific stock opened at $95.98 on Wednesday. The stock has a market cap of $142.28 billion, a price-to-earnings ratio of 51.32, a P/E/G ratio of 1.93 and a beta of 0.67. Boston Scientific Corporation has a twelve month low of $85.98 and a twelve month high of $109.50. The company’s fifty day moving average is $98.36 and its 200 day moving average is $101.05. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The firm had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.97 billion. During the same period in the previous year, the business earned $0.63 EPS. The business’s quarterly revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Sell-side analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. UBS Group restated a “buy” rating on shares of Boston Scientific in a research note on Wednesday, December 17th. Barclays increased their price objective on shares of Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research note on Thursday, October 2nd. Needham & Company LLC restated a “buy” rating and issued a $121.00 target price on shares of Boston Scientific in a research report on Friday, October 17th. Evercore ISI reiterated an “outperform” rating on shares of Boston Scientific in a report on Wednesday, October 22nd. Finally, BTIG Research reiterated a “buy” rating and issued a $132.00 price target on shares of Boston Scientific in a research note on Friday, November 21st. Two investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $124.85.

Insider Buying and Selling

In other news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the transaction, the executive vice president owned 23,600 shares in the company, valued at approximately $2,396,580. The trade was a 42.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the sale, the director owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This trade represents a 34.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 93,095 shares of company stock valued at $9,305,450 over the last ninety days. 0.50% of the stock is owned by company insiders.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.